Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
28 Results for "
drug-resistant Mycobacterium tuberculosis
" in MedChemExpress (MCE) Product Catalog:
Products (28)
28 Results for "drug-resistant Mycobacterium tuberculosis" in MCE Product Catalog:
66
66 Cited Publications
Cat. No.: HY-135748A
Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .
4
Target:
Research Areas:
SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM) .
Cat. No.: HY-W040128
CAS No.: 70560-51-9
Target:
Research Areas:
Kanamycins sulfate is a blood-brain barrier-permeable JNK1 and Bcl-2 modulator as well as an antibiotic, with broad-spectrum antibacterial, and biofilm-inhibiting activities, and it induces autophagy. Kanamycins sulfate promotes Bcl-2 phosphorylation to upregulate autophagy levels, triggering changes such as mitochondrial swelling and endoplasmic reticulum expansion. Consequently, it causes reversible neuronal damage in the dorsal cochlear nucleus without inducing significant neuronal apoptosis. In the presence of exogenous alanine or glucose, Kanamycins sulfate effectively kills drug-resistant bacteria, restores drug sensitivity of multidrug-resistant bacteria, and alleviates urinary tract and kidney infections in mice. Kanamycins sulfate can be applied to scientific research related to Mycobacterium tuberculosis, salmonellosis, brucellosis, shigellosis, urinary tract infections, and reversible neurotoxicity .
Cat. No.: HY-125576
CAS No.: 26034-16-2
Target:
Research Areas:
TBA-354 is an orally active, blood-brain barrier permeable anti-tuberculosis compound . TBA-354 acts on replicating, non-replicating and drug-resistant Mycobacterium tuberculosis, retains its activity in the presence of serum proteins or albumin, and induces moderate, reversible neurotoxicity at effective dose levels. TBA-354 can be used in the research of tuberculosis and multidrug-resistant tuberculosis .
Cat. No.: HY-113619
CAS No.: 186293-38-9
ABT-255 free base is an orally active anti-bacterial agent. ABT-255 free base exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin (HY-B0272)- or Ethambutol (HY-B0535)-resistant Mycobacterium tuberculosis. ABT-255 free base shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 free base can be used for the study of pulmonary tuberculosis .
Cat. No.: HY-114604
CAS No.: 102962-95-8
Category:
Target:
Cat. No.: HY-162508
KSK-104 has potent antibacterial activity against Mycobacterium tuberculosis (MIC=0.78 μM). The role of KSK-104 is mainly involved in the synthesis and recovery pathways of pyridoxal 5'-phosphate (PLP), PLP-dependent enzymes and oxidative stress networks. KSK-104, as a candidate molecule for novel anti-tuberculosis drugs, can be used to develop research against drug-resistant mycobacterium tuberculosis .
Cat. No.: HY-149346
CAS No.: 2861190-30-7
Mtb-IN-2 (compound 10c) is an antimicrobial agent against Mycobacterium tuberculosis (Mtb), without cytotoxicity. Mtb-IN-2 significantly decreases colony-forming units (CFU) in spleen of murine tuberculosis models, and distinguishes both drug-sensitive and drug-resistant Mtb H37Rv strains. Mtb-IN-2 affects methionine metabolism but not folate pathway directly.
Cat. No.: HY-113619A
CAS No.: 181141-52-6
ABT-255 hydrochloride is an orally active anti-bacterial agent. ABT-255 hydrochloride exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin (HY-B0272)- or Ethambutol (HY-B0535)-resistant Mycobacterium tuberculosis. ABT-255 hydrochloride shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 hydrochloride can be used for the study of pulmonary tuberculosis .
Cat. No.: HY-12485R
CAS No.: 1257426-19-9
Target:
Research Areas:
TBA-354 (Standard) is the analytical standard of TBA-354 (HY-12485). This product is intended for research and analytical applications. TBA-354 is an orally active, blood-brain barrier permeable anti-tuberculosis compound . TBA-354 acts on replicating, non-replicating and drug-resistant Mycobacterium tuberculosis, retains its activity in the presence of serum proteins or albumin, and induces moderate, reversible neurotoxicity at effective dose levels. TBA-354 can be used in the research of tuberculosis and multidrug-resistant tuberculosis .
Cat. No.: HY-W353258R
CAS No.: 192927-63-2
Synonyms: BAY 12-8039 monohydrate (Standard)
Research Areas:
Moxifloxacin hydrochloride (BAY 12-8039) monohydrate (Standard) is the analytical standard of Moxifloxacin hydrochloride monohydrate. This product is intended for research and analytical applications. Moxifloxacin hydrochloride monohydrate is a blood-brain barrier-permeable, orally active topoisomerase II/IV inhibitor and a fluoroquinolone antibiotic. Moxifloxacin hydrochloride monohydrate disrupts bacterial DNA replication, transcription, repair and chromosome segregation processes. Moxifloxacin hydrochloride monohydrate exhibits activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, atypical pathogens, drug-resistant respiratory pathogens, Mycobacterium tuberculosis, mycoplasmas and Ureaplasma urealyticum.
Cat. No.: HY-170970
Mtb-IN-10 (Compound P15) is a Rv1625c/Cya activator that regulates cAMP metabolism to influence the growth of Mycobacterium tuberculosis (Mtb). Mtb-IN-10 exhibits an EC50 of 1.96 µM in an Mtb-infected macrophage model and demonstrates 58.0% oral bioavailability in mice at a 20 mg/kg dose. It may regulate intracellular signaling and disrupt cholesterol metabolism in Mtb, thereby inhibiting bacterial proliferation. Mtb-IN-10 holds potential for tuberculosis (TB) research, particularly for combating multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) Mtb strains .
Cat. No.: HY-175016
Target:
Research Areas:
NADH-IN-3 (Compound C4-1) is a NADH inhibitor with a MIC of 4 μg/mL (13.042 μM) for type II NADH dehydrogenase of Mycobacterium tuberculosis (Mtb). NADH-IN-3 significantly interrupts ATP synthesis, shows potent inhibitory effects against mono (Rifampicin (HY-B0272) and Isoniazid (HY-B0329)) and multi drug-resistant (Mtb) strains and an anti-bactericidal activity against HepG2 cells with low cytotoxicity (SI: 16.52) .
Cat. No.: HY-183606
Mycobacterium tuberculosis-IN-9 is an orally active Mycobacterium tuberculosis BioA inhibitor with a Ki value of 0.2 nM. Mycobacterium tuberculosis-IN-9 targets the biotin biosynthesis pathway. Mycobacterium tuberculosis-IN-9 inhibits the growth of Mycobacterium tuberculosis in mouse models and is effective against both drug-sensitive and drug-resistant strains. Mycobacterium tuberculosis-IN-9 can be used for the research of tuberculosis .
Cat. No.: HY-184685
Target:
Research Areas:
Antimycobacterial agent-18 is a mycobacterial Fatty Acid Synthase I (FAS I) system inhibitor. Antimycobacterial agent-18 shows antimycobacterial activity against Mycobacterium tuberculosis H37Ra and drug-resistant Mycobacterium tuberculosis isolates, and partial activity against Mycobacterium abscessus. Antimycobacterial agent-18 can be used for the research of tuberculosis .
Cat. No.: HY-184411
CAS No.: 3104768-44-4
TB-212 is a potent, orally active anti-tuberculosis agent. TB-212 exhibits activity against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains, with favorable safety profiles. TB-212 is applicable to the research of tuberculosis .
Cat. No.: HY-L142
159 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.
Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.
MCE supplies a unique collection of 159 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development
Cat. No.: HY-181866
CAS No.: 2670430-25-6
Antibacterial agent 328 is a enoyl-ACP reductase (InhA) inhibitor and antimycobacterial agent. Antibacterial agent 328 blocks mycolic acid biosynthesis in Mycobacterium tuberculosis. Antibacterial agent 328 acts on both drug-resistant and drug-susceptible Mycobacterium tuberculosis strains. Antibacterial agent 328 exhibits favorable pharmacokinetic properties, drug-likeness, and a safety-related selectivity index. Antibacterial agent 328 can be used for research on tuberculosis .
Cat. No.: HY-183323
MmpL3-IN-6 is a mycobacterial membrane protein large 3 (MmpL3) transporter inhibitor and is an antitubercular agent. MmpL3-IN-6 exerts bactericidal activity against replicating Mycobacterium tuberculosis.MmpL3-IN-6 retains activity against drug-resistant Mycobacterium tuberculosis.MmpL3-IN-6 can be used for the research of tuberculosis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
